CoChat
Sign Up
Cited by 19

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Morphologically transformable peptide nanocarriers coloaded with doxorubicin and curcumin inhibit the growth and metastasis of hepatocellular carcinoma

Liu, Yun, Liu, Yunxia, Sun, Xinyu, Wang, Yue, Du, Changqing, Bai, Jingkun·2024·Materials Today Bio
DOI 10.1016/j.mtbio.2023.100903PMC PMC10733681
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mtbio.2023.100903

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract Graphical abstract Novel NPs of DC/Pep1 for Cancer Therapy. Pep1 encapsulated with DOX and CUR can self-assemble to form NPs (DC/Pep1), which can be targeted to the tumor vasculature and enter the tumor microenvironment in the presence of CREKA. DC/Pep1 undergoes morphological transformations in the acidic tumor microenvironment, resulting in drug release and prolonging drug retention in the tumor tissues in vivo. DC/Pep1 inhibits angiogenesis, promotes DC/Pep1 inhibition of angiogenesis, promotes apoptosis, and inhibits C–C motif chemokine 2 (CCL-2), resulting in effective inhibition of lung metastasis and synergistic antitumor effects.
Graphical abstract Graphical abstract Novel NPs of DC/Pep1 for Cancer Therapy. Pep1 encapsulated with DOX and CUR can self-assemble to form NPs (DC/Pep1), which can be targeted to the tumor vasculature and enter the tumor microenvironment in the presence of CREKA. DC/Pep1 undergoes morphological transformations in the acidic tumor microenvironment, resulting in drug release and prolonging drug retention in the tumor tissues in vivo. DC/Pep1 inhibits angiogenesis, promotes DC/Pep1 inhibition of angiogenesis, promotes apoptosis, and inhibits C–C motif chemokine 2 (CCL-2), resulting in effective inhibition of lung metastasis and synergistic antitumor effects.CC BY-NC-ND · PubMed Central
Fig. 1 Novel NPs of DC/Pep1 for Cancer Therapy. Pep1 encapsulated with DOX and CUR can self-assemble to form NPs (DC/Pep1), which can be targeted to the tumor vasculature and enter the tumor microenvironment in the presence of CREKA. DC/Pep1 undergoes morphological transformations in the acidic tumor microenvironment, resulting in drug release and prolonging drug retention in the tumor tissues in vivo. DC/Pep1 inhibits angiogenesis, promotes apoptosis, and inhibits C–C motif chemokine ligand-2 (CCL-2), resulting in effective inhibition of lung metastasis and synergistic antitumor effects (by Figdraw).
Fig. 1 Novel NPs of DC/Pep1 for Cancer Therapy. Pep1 encapsulated with DOX and CUR can self-assemble to form NPs (DC/Pep1), which can be targeted to the tumor vasculature and enter the tumor microenvironment in the presence of CREKA. DC/Pep1 undergoes morphological transformations in the acidic tumor microenvironment, resulting in drug release and prolonging drug retention in the tumor tissues in vivo. DC/Pep1 inhibits angiogenesis, promotes apoptosis, and inhibits C–C motif chemokine ligand-2 (CCL-2), resulting in effective inhibition of lung metastasis and synergistic antitumor effects (by Figdraw).CC BY-NC-ND · PubMed Central
Fig. 2 Characterization and Cytotoxicity Assay of Peptides. (a) Structures of Pep1 and Pep2. (b) TEM images of Pep1, DC/Pep1, DC/Pep1 (pH 5), Pep2, DC/Pep2, and DC/Pep2 (pH 5). Scale bar: 100 nm. (c) Viability of HepG2 cells and HUVECs after 48 h of peptide treatment. **P < 0.01; ***P < 0.001. (d) Changes in the zeta potentials of Pep1, DC/Pep1 and DC/Pep1 at pH 5 after 12 h and 120 h and the changes in Pep2 potential after the same treatments. (e) Cumulative DOX and CUR release profiles from Pep1 before and after the addition of acid.
Fig. 2 Characterization and Cytotoxicity Assay of Peptides. (a) Structures of Pep1 and Pep2. (b) TEM images of Pep1, DC/Pep1, DC/Pep1 (pH 5), Pep2, DC/Pep2, and DC/Pep2 (pH 5). Scale bar: 100 nm. (c) Viability of HepG2 cells and HUVECs after 48 h of peptide treatment. **P < 0.01; ***P < 0.001. (d) Changes in the zeta potentials of Pep1, DC/Pep1 and DC/Pep1 at pH 5 after 12 h and 120 h and the changes in Pep2 potential after the same treatments. (e) Cumulative DOX and CUR release profiles from Pep1 before and after the addition of acid.CC BY-NC-ND · PubMed Central
Fig. 3 Effects of Pep1 on Tumor Cell Uptake, Retention and Migration. CLSM images of HepG2 cells coexisting with DC, DC/Pep2, and DC/Pep1 for (a) 0.25 h and (b) 0.5 h. Scale bar: 50 μm. Uptake of DOX and CUR in HepG2 cells after coculture with DC, DC/Pep2, and DC/Pep1 for (c) 0.25 h and (d) 0.5 h was detected by FCM. (e) CLSM images of HepG2 cells cocultivated with DC, DC/Pep2, and DC/Pep1 for 72 h. Scale bar: 50 μm. (f) WB images indicating Vimentin and E-cadherin and (g) quantitative analysis. (h) Quantitative evaluation of HepG2 cells at 24 h and 48 h intervals following the scratch assay. *P < 0.05; **P < 0.01; ***P < 0.001; ns, P > 0.05 relative to DC/Pep1.
Fig. 3 Effects of Pep1 on Tumor Cell Uptake, Retention and Migration. CLSM images of HepG2 cells coexisting with DC, DC/Pep2, and DC/Pep1 for (a) 0.25 h and (b) 0.5 h. Scale bar: 50 μm. Uptake of DOX and CUR in HepG2 cells after coculture with DC, DC/Pep2, and DC/Pep1 for (c) 0.25 h and (d) 0.5 h was detected by FCM. (e) CLSM images of HepG2 cells cocultivated with DC, DC/Pep2, and DC/Pep1 for 72 h. Scale bar: 50 μm. (f) WB images indicating Vimentin and E-cadherin and (g) quantitative analysis. (h) Quantitative evaluation of HepG2 cells at 24 h and 48 h intervals following the scratch assay. *P < 0.05; **P < 0.01; ***P < 0.001; ns, P > 0.05 relative to DC/Pep1.CC BY-NC-ND · PubMed Central
Fig. 4 Effects of Drug-loaded Peptides on HepG2 Cell Apoptosis and Angiogenesis. (a) WB analysis and (b) quantitative analysis of Caspase-3 activation. (c) Flow chart of HepG2 cell apoptosis (Q1: necrotic cells; Q2: late apoptotic cells; Q3: early apoptotic cells; and Q4: live cells) and (d) quantitative analysis. (e) Representative photographs and (f) quantitative analysis of the numbers of tubes formed and the capture of tubular structures in HUVECs. Scale bar: 200 μm. *P < 0.05; **P < 0.01; ***P < 0.001; ns, P > 0.05 relative to DC/Pep1.
Fig. 4 Effects of Drug-loaded Peptides on HepG2 Cell Apoptosis and Angiogenesis. (a) WB analysis and (b) quantitative analysis of Caspase-3 activation. (c) Flow chart of HepG2 cell apoptosis (Q1: necrotic cells; Q2: late apoptotic cells; Q3: early apoptotic cells; and Q4: live cells) and (d) quantitative analysis. (e) Representative photographs and (f) quantitative analysis of the numbers of tubes formed and the capture of tubular structures in HUVECs. Scale bar: 200 μm. *P < 0.05; **P < 0.01; ***P < 0.001; ns, P > 0.05 relative to DC/Pep1.CC BY-NC-ND · PubMed Central
Fig. 5 Distribution of DiR in H22 Tumor-Bearing Mice in Vivo and in Isolated Tumors and Major Organs. (a) Fluorescence images of live mice were observed in vivo following the administration of DiR, DiR/Pep2 and DiR/Pep1 via intravenous injection during specific time intervals. (b) Fluorescence images of tissues ex vivo at the designated time intervals and (c) quantitative analysis. *P < 0.05; **P < 0.01.
Fig. 5 Distribution of DiR in H22 Tumor-Bearing Mice in Vivo and in Isolated Tumors and Major Organs. (a) Fluorescence images of live mice were observed in vivo following the administration of DiR, DiR/Pep2 and DiR/Pep1 via intravenous injection during specific time intervals. (b) Fluorescence images of tissues ex vivo at the designated time intervals and (c) quantitative analysis. *P < 0.05; **P < 0.01.CC BY-NC-ND · PubMed Central
Fig. 6 In Vivo Antitumor Effects. (a) In vivo antitumor assay. (b) Images, (c) weights and (d) volumes of H22 tumors excised on day 14. (e) Rates of tumor inhibition achieved. (f) Differences in the weight of mice with tumors. *P < 0.05; **P < 0.01; ***P < 0.001.
Fig. 6 In Vivo Antitumor Effects. (a) In vivo antitumor assay. (b) Images, (c) weights and (d) volumes of H22 tumors excised on day 14. (e) Rates of tumor inhibition achieved. (f) Differences in the weight of mice with tumors. *P < 0.05; **P < 0.01; ***P < 0.001.CC BY-NC-ND · PubMed Central
Fig. 7 Representative Histological Images of the Main Organs and Tumors of H22 Tumor-Bearing Mice after Different Treatments (Saline, DC, DOX/Pep2, DOX/Pep1, DC/Pep2, DC/Pep1). (a) After various treatments, the heart, liver, spleen, lung, kidney and tumor tissues of mice with tumors were examined using H&E staining. Scale bar: 30 μm. (b) Immunohistological staining for CD31 and (c) TUNEL staining of tumor sections treated with different medications. Scale bar: 30 μm.
Fig. 7 Representative Histological Images of the Main Organs and Tumors of H22 Tumor-Bearing Mice after Different Treatments (Saline, DC, DOX/Pep2, DOX/Pep1, DC/Pep2, DC/Pep1). (a) After various treatments, the heart, liver, spleen, lung, kidney and tumor tissues of mice with tumors were examined using H&E staining. Scale bar: 30 μm. (b) Immunohistological staining for CD31 and (c) TUNEL staining of tumor sections treated with different medications. Scale bar: 30 μm.CC BY-NC-ND · PubMed Central
Fig. 8 Antimetastatic Effects of Different Preparations in the H22 Tumor Model. (a) In vivo antimetastasis assay in tumor-bearing mice. (b) Images of lung metastasis and (c) the count of nodules with lung metastases. **P < 0.01; ***P < 0.001; ns, P > 0.05. (d) Body weight increase patterns of mice throughout the duration of the treatment. (e) H&E-stained lung sections. Scale bar: 50 μm. (f) The levels of CCL-2 in lung sections determined by immunofluorescence. Scale bar: 50 μm.
Fig. 8 Antimetastatic Effects of Different Preparations in the H22 Tumor Model. (a) In vivo antimetastasis assay in tumor-bearing mice. (b) Images of lung metastasis and (c) the count of nodules with lung metastases. **P < 0.01; ***P < 0.001; ns, P > 0.05. (d) Body weight increase patterns of mice throughout the duration of the treatment. (e) H&E-stained lung sections. Scale bar: 50 μm. (f) The levels of CCL-2 in lung sections determined by immunofluorescence. Scale bar: 50 μm.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 65

  1. Rumgay, 2022, Global burden of primary liver cancer in 2020 and predictions to 2040, J. Hepatol., 77, 1598, 10.1016/j.jhep.2022.08.021 · DOI · Paper page
  2. Anwanwan, 2020, Challenges in liver cancer and possible treatment approaches, Biochim. Biophys. Acta, Rev. Cancer., 1873, 10.1016/j.bbcan.2019.188314 · DOI
  3. Larionova, 2019, 2026P - the clearance of EGF by tumor-associated macrophages is suppressed by chemotherapeutic agent cisplatin, Ann. Oncol., 30, v810, 10.1093/annonc/mdz269.043 · DOI
  4. Zhang, 2023, Polysaccharide-based nanocarriers for efficient transvascular drug delivery, J. Controlled Release, 354, 167, 10.1016/j.jconrel.2022.12.051 · DOI
  5. Tahmasbi Rad, 2019, Combinational effects of active targeting, shape, and enhanced permeability and retention for cancer theranostic nanocarriers, ACS Appl. Mater. Interfaces, 11, 10505, 10.1021/acsami.8b21609 · DOI
  6. Sun, 2014, Integration of nanoassembly functions for an effective delivery cascade for cancer drugs, Adv. Mater., 26, 7615, 10.1002/adma.201401554 · DOI
  7. Xu, 2022, pH-Sensitive nanoparticles based on amphiphilic imidazole/cholesterol modified hydroxyethyl starch for tumor chemotherapy, Carbohydr. Polym., 277, 10.1016/j.carbpol.2021.118827 · DOI
  8. Jia, 2019, Construction of dually responsive nanotransformers with nanosphere-nanofiber-nanosphere transition for overcoming the size paradox of anticancer nanodrugs, ACS Nano, 13, 11781, 10.1021/acsnano.9b05749 · DOI
  9. Hinde, 2017, Pair correlation microscopy reveals the role of nanoparticle shape in intracellular transport and site of drug release, Nat. Nanotechnol., 12, 81, 10.1038/nnano.2016.160 · DOI
  10. Jia, 2022, Dual-responsive nanoparticles with transformable shape and reversible charge for amplified chemo-photodynamic therapy of breast cancer, Acta Pharm. Sin. B, 12, 3354, 10.1016/j.apsb.2022.03.010 · DOI
  11. Farzin, 2021, Self-oxygenation of tissues orchestrates full-thickness vascularization of living implants, Adv. Funct. Mater., 31
  12. Jia, 2021, Shape transformable strategies for drug delivery, Adv. Funct. Mater., 31, 10.1002/adfm.202009765 · DOI
  13. Lin, 2020, GSH-responsive SN38 dimer-loaded shape-transformable nanoparticles with iRGD for enhancing chemo-photodynamic therapy, Acta Pharm. Sin. B, 10, 2348, 10.1016/j.apsb.2020.10.009 · DOI
  14. Liu, 2020, Macrophage-mimic shape changeable nanomedicine retained in tumor for multimodal therapy of breast cancer, J. Controlled Release, 321, 589, 10.1016/j.jconrel.2020.02.043 · DOI
  15. Gong, 2020, Plasma amine oxidase-induced nanoparticle-to-nanofiber geometric transformation of an peptide for drug encapsulation and enhanced bactericidal activity, ACS Appl. Mater. Interfaces, 12, 4323, 10.1021/acsami.9b21296 · DOI
  16. Gong, 2021, Enzyme-induced transformable peptide nanocarriers with enhanced drug permeability and retention to improve tumor nanotherapy efficacy, ACS Appl. Mater. Interfaces, 13, 55913, 10.1021/acsami.1c17917 · DOI
  17. Boedtkjer, 2020, The acidic tumor microenvironment as a driver of cancer, Annu. Rev. Physiol., 82, 103, 10.1146/annurev-physiol-021119-034627 · DOI
  18. Feng, 2018, The acidic tumor microenvironment: a target for smart cancer nano-theranostics, Natl. Sci. Rev., 5, 269, 10.1093/nsr/nwx062 · DOI
  19. Meng, 2022, Self-enhanced acoustic impedance difference strategy for detecting the acidic tumor microenvironment, ACS Nano, 16, 4217, 10.1021/acsnano.1c10173 · DOI
  20. Yang, 2020, Multi-transformable nanocarrier with tumor extracellular acidity-activated charge reversal, size reduction and ligand reemergence for in vitro efficient doxorubicin loading and delivery, Mater. Sci. Eng. C, 116, 10.1016/j.msec.2020.111250 · DOI
  21. Wu, 2023, A transcriptomic pan-cancer signature for survival prognostication and prediction of immunotherapy response based on endothelial senescence, J. Biomed. Sci., 30, 21, 10.1186/s12929-023-00915-5 · DOI
  22. Li, 2023, Recent progress in advanced hydrogel-based embolic agents: from rational design strategies to improved endovascular embolization, Adv. Healthcare Mater., 12
  23. Hong, 2022, Vascular disrupting agent-induced amplification of tumor targeting and prodrug activation boosts anti-tumor efficacy, Sci. China: Chem., 65, 1994, 10.1007/s11426-022-1347-9 · DOI
  24. Nowak-Sliwinska, 2023, Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy, Angiogenesis, 26, 279, 10.1007/s10456-022-09863-4 · DOI
  25. Agemy, 2010, Nanoparticle-induced vascular blockade in human prostate cancer, Blood, 116, 2847, 10.1182/blood-2010-03-274258 · DOI
  26. Zhang, 2023, Recent advances of CREKA peptide-based nanoplatforms in biomedical applications, J. Nanobiotechnol., 21, 77, 10.1186/s12951-023-01827-0 · DOI
  27. Li, 2020, A bioinspired nanoprobe with multilevel responsive T (1) -weighted MR signal-amplification illuminates ultrasmall metastases, Adv. Mater., 32
  28. Ashrafizadeh, 2021, Hyaluronic acid-based nanoplatforms for Doxorubicin: a review of stimuli-responsive carriers, co-delivery and resistance suppression, Carbohydr. Polym., 272, 10.1016/j.carbpol.2021.118491 · DOI
  29. Mohammad, 2023, Nanocomplexes of doxorubicin and DNA fragments for efficient and safe cancer chemotherapy, J. Controlled Release, 354, 91, 10.1016/j.jconrel.2022.12.048 · DOI
  30. Li, 2023, A micelle-based stage-by-stage impelled system for efficient doxorubicin delivery, Bioact. Mater., 25, 783
  31. Zhang, 2021, An efficient carbon-based drug delivery system for cancer therapy through the nucleus targeting and mitochondria mediated apoptotic pathway, Small Methods, 5, 10.1002/smtd.202100539 · DOI
  32. Zeien, 2022, Clinical implications of chemotherapeutic agent organ toxicity on perioperative care, Biomed. Pharmacother., 146, 10.1016/j.biopha.2021.112503 · DOI
  33. Gao, 2022, Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment, Adv. Drug Delivery Rev., 188, 10.1016/j.addr.2022.114445 · DOI
  34. Araveti, 2019, Curcumin induced oxidative stress causes autophagy and apoptosis in bovine leucocytes transformed by Theileria annulata, Cell Death Discovery, 5, 100, 10.1038/s41420-019-0180-8 · DOI
  35. Daya, 2022, Angiogenic hyaluronic acid hydrogels with curcumin-coated magnetic nanoparticles for tissue repair, ACS Appl. Mater. Interfaces., 14, 11051, 10.1021/acsami.1c19889 · DOI
  36. Yang, 2018, A modular coassembly approach to all-in-one multifunctional nanoplatform for synergistic codelivery of doxorubicin and curcumin, Nanomaterials, 8, 167, 10.3390/nano8030167 · DOI
  37. Jin, 2019, Rational design of cancer nanomedicine for simultaneous stealth surface and enhanced cellular uptake, ACS Nano, 13, 954
  38. Zhang, 2021, Nanoparticulation of prodrug into medicines for cancer therapy, Adv. Sci., 8, 10.1002/advs.202101454 · DOI
  39. Cao, 2023, Enzyme-induced morphological transformation of self-assembled peptide nanovehicles potentiates intratumoral aggregation and inhibits tumour immunosuppression, Chem. Eng. J., 454, 10.1016/j.cej.2022.140466 · DOI
  40. Cao, 2023, Matrix metalloproteinase-2-induced morphologic transformation of self-assembled peptide nanocarriers inhibits tumor growth and metastasis, ACS Mater. Lett., 5, 900, 10.1021/acsmaterialslett.2c01093 · DOI
  41. Hao, 2022, Rational design of ibuprofen-based redox-responsive anti-cancer polymeric drug delivery systems, J. Mater. Sci., 57, 11317, 10.1007/s10853-022-07347-w · DOI
  42. Lin, 2022, Preparation, characterization and antioxidant properties of curcumin encapsulated chitosan/lignosulfonate micelles, Carbohydr. Polym., 281, 10.1016/j.carbpol.2021.119080 · DOI
  43. Korenchan, 2019, Spatiotemporal pH heterogeneity as a promoter of cancer progression and therapeutic resistance, Cancers, 11, 1026, 10.3390/cancers11071026 · DOI
  44. Li, 2015, Enzyme-instructed intracellular molecular self-assembly to boost activity of cisplatin against drug-resistant ovarian cancer cells, Angew. Chem., 54, 13307, 10.1002/anie.201507157 · DOI
  45. Ingato, 2018, Cancer cell-derived, drug-loaded nanovesicles induced by sulfhydryl-blocking for effective and safe cancer therapy, ACS Nano, 12, 9568, 10.1021/acsnano.8b05377 · DOI
  46. Sasaki, 2019, Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy, Sci. Adv., 5, 10.1126/sciadv.aaw6081 · DOI
  47. Teo, 2016, Co-delivery of drugs and plasmid DNA for cancer therapy, Adv. Drug Delivery Rev., 98, 41, 10.1016/j.addr.2015.10.014 · DOI
  48. Cho, 2009, Understanding the role of surface charges in cellular adsorption versus internalization by selectively removing gold nanoparticles on the cell surface with a I2/KI etchant, Nano Lett., 9, 1080, 10.1021/nl803487r · DOI
  49. Tao, 2016, Cholesterol-Modified amino-pullulan nanoparticles as a drug carrier: comparative study of cholesterol-modified carboxyethyl pullulan and pullulan nanoparticles, Nanomaterials, 6, 165, 10.3390/nano6090165 · DOI
  50. Chen, 2011, The role of surface charge on the uptake and biocompatibility of hydroxyapatite nanoparticles with osteoblast cells, Nanotechnology, 22
  51. Baoum, 2010, Cationic surface modification of PLG nanoparticles offers sustained gene delivery to pulmonary epithelial cells, J. Pharmaceut. Sci., 99, 2413, 10.1002/jps.21994 · DOI
  52. Lu, 2022, CRPC membrane-camouflaged, biomimetic nanosystem for overcoming castration-resistant prostate cancer by cellular vehicle-aided tumor targeting, Int. J. Mol. Sci., 23, 3623, 10.3390/ijms23073623 · DOI
  53. Ang, 2023, Mechanism of epithelial-mesenchymal transition in cancer and its regulation by natural compounds, Med. Res. Rev., 43, 1141, 10.1002/med.21948 · DOI
  54. Hsu, 2007, KCl cotransporter-3 down-regulates E-cadherin/beta-catenin complex to promote epithelial-mesenchymal transition, Cancer Res., 67, 11064, 10.1158/0008-5472.CAN-07-2443 · DOI
  55. Bock, 2021, Apoptotic stress-induced FGF signalling promotes non-cell autonomous resistance to cell death, Nat. Commun., 12, 6572, 10.1038/s41467-021-26613-0 · DOI
  56. Bertheloot, 2021, Necroptosis, pyroptosis and apoptosis: an intricate game of cell death, Cell. Mol. Immunol., 18, 1106, 10.1038/s41423-020-00630-3 · DOI
  57. Rogers, 2019, Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation, Nat. Commun., 10, 1689, 10.1038/s41467-019-09397-2 · DOI
  58. Abedi, 2021, An improved method in fabrication of smart dual-responsive nanogels for controlled release of doxorubicin and curcumin in HT-29 colon cancer cells, J. Nanobiotechnol., 19, 18, 10.1186/s12951-020-00764-6 · DOI · Paper page
  59. Tavora, 2020, Tumoural activation of TLR3-SLIT2 axis in endothelium drives metastasis, Nature, 586, 299, 10.1038/s41586-020-2774-y · DOI
  60. Jhaveri, 2016, Intracellular delivery of nanocarriers and targeting to subcellular organelles, Expet Opin. Drug Delivery, 13, 49, 10.1517/17425247.2015.1086745 · DOI
  61. Meng, 2017, Hsp90β promoted endothelial cell-dependent tumor angiogenesis in hepatocellular carcinoma, Mol. Cancer, 16, 72, 10.1186/s12943-017-0640-9 · DOI
  62. Wang, 2020, Fluorescence-guided fiber-optic micronavigation using microscopic identification of vascular boundary of liver segment and tumors, Theranostics, 10, 6136, 10.7150/thno.45973 · DOI
  63. Wang, 2019, Extracellular vesicles (EVs) from lung adenocarcinoma cells promote human umbilical vein endothelial cell (HUVEC) angiogenesis through yes kinase-associated protein (YAP) transport, Int. J. Biol. Sci., 15, 2110, 10.7150/ijbs.31605 · DOI
  64. Charpin, 2004, Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays, Clin. Cancer Res., 10, 5815, 10.1158/1078-0432.CCR-04-0021 · DOI
  65. Gening, 2021, IL-17A and CCL2 in blood serum and circulating neutrophils in patients with ovarian tumors, J. Clin. Oncol., 39, 10.1200/JCO.2021.39.15_suppl.e17536 · DOI

Cited by

Sorted by citations

Metadata

Authors
Liu, Y., Liu, Y., Sun, X., Wang, Y., Du, C., & Bai, J.
Venue
Materials Today Bio
Publisher
Elsevier BV
Published
2024-02
Volume
24
Pages
100903
ISSN
2590-0064
DOI
10.1016/j.mtbio.2023.100903
PMC
PMC10733681
Cited by
19
References
1
Language
en
Licence
Funders
Natural Science Foundation of Shandong Province (ZR2023MC122)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review